论文部分内容阅读
目的评估变应性鼻炎(AR)患者联合用药、单独鼻用激素维持治疗的疗效及生活质量。方法 24例中重度持续性AR患者,使用布地奈德鼻喷雾剂和口服氯雷他定1周治疗。18例显效患者随机分为布地奈德维持用药实验组(11例)和停止用药对照组(7例)。通过临床症状、视觉模拟评分(visual analogue scale,VAS)及鼻结膜炎相关生活质量问卷(rhinoconjunctivitis quality of Life questionnaire,RQLQ)进行评估。结果联合用药1周,临床症状及生活质量均得到显著性改善(P<0.01),治疗总有效率为91.7%(22/24)。在维持治疗1个月后,实验组与对照组症状评分较联合治疗结束时显著性升高(P<0.01);VAS及RQLQ评分亦升高,但差异无显著性。结论对中重度持续性AR联合用药可有效控制症状,症状控制后鼻用激素维持治疗可改善生活质量。
Objectives To assess the efficacy and quality of life of patients with allergic rhinitis (AR) in combination with hormone therapy alone. Methods Twenty-four patients with moderate-to-severe persistent AR were treated with budesonide nasal spray and oral loratadine for one week. Eighteen patients with marked effects were randomly divided into budesonide maintenance medication group (n = 11) and cessation drug control group (n = 7). Clinical symptoms, visual analogue scale (VAS), and rhinoconjunctivitis quality of life questionnaire (RQLQ) were evaluated. Results One week after the combination therapy, the clinical symptoms and quality of life were significantly improved (P <0.01). The total effective rate was 91.7% (22/24). After 1 month of maintenance treatment, symptom score of experimental group and control group increased significantly (P <0.01), while VAS and RQLQ scores also increased, but the difference was not significant. Conclusions The combination of moderate and severe persistent AR can effectively control the symptoms and the nasal administration of hormones after the symptom control can improve the quality of life.